Cardiff Oncology, Inc.CRDFNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -3.21% | -46.83% | -25.77% | -27.27% | +60.93% |
| Gross Profit Growth | +184.91% | +5.83% | -19856.90% | +0.00% | -86.75% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +6.65% | +48.90% | +48.41% | +42.71% | +40.27% |
| Weighted Average Shares Diluted Growth | +6.65% | +6.65% | +48.41% | +42.71% | +40.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +168.40% | +3.05% | +16.63% | -58.90% | -76.46% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +19.05% | +14.55% | +14.67% | +1.41% | -36.33% |
| Book Value per Share Growth | +11.52% | -21.83% | -24.62% | -30.78% | -60.99% |
| Debt Growth | -29.13% | -32.10% | -35.70% | -40.09% | -45.37% |
| R&D Expense Growth | +25.11% | +30.83% | +21.98% | -14.97% | -47.75% |
| SG&A Expenses Growth | +10.50% | +32.56% | -100.00% | +0.00% | -0.53% |